Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

• Status: Active, not recruiting
• Trial end date: 2022-07-06

Summary

This pilot trial studies how well chemokine modulation therapy works when given prior to pembrolizumab in treating participants with triple-negative breast cancer that has spread to other places in the body. Drugs used in chemokine modulation therapy, such as celecoxib, recombinant interferon alfa-2b, and rintatolimod, work by unleashing or enhancing the cancer immune responses that already exist by either blocking inhibitory molecules or by activating stimulatory molecules. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving chemokine modulation therapy before pembrolizumab may work better in treating participants with metastatic triple-negative breast cancer

• Phase: Early Phase 1

Details

• Lead Sponsor: Roswell Park Cancer Institute
• Collaborator: AIM ImmunoTech Inc.
• Treatments: Benzenesulfonamide; Celecoxib; Immunoglobulin G; Immunoglobulins; Interferon alpha-2; Interferon-alpha; Interferons; Pembrolizumab; Poly I-C; poly(I).poly(c12,U)